Idarubicin-containing regimen and G-CSF are capable of recruiting CD34+/DR- cells with high proliferative potential which sustain Ph-negative polyclonal hematopoiesis

Leukemia. 1994 Jan;8(1):212-3.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antigens, CD / immunology*
  • Antigens, CD34
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cell Division / physiology
  • Cytarabine / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • HLA-DR Antigens / immunology*
  • Hematopoiesis / drug effects*
  • Hematopoiesis / immunology
  • Hematopoiesis / physiology*
  • Humans
  • Idarubicin / administration & dosage
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / drug therapy*
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / genetics
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / immunology
  • Male
  • Middle Aged

Substances

  • Antigens, CD
  • Antigens, CD34
  • HLA-DR Antigens
  • Cytarabine
  • Granulocyte Colony-Stimulating Factor
  • Etoposide
  • Idarubicin